Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

408 publications
Année de publication :
Réseaux :

Environmental chemicals, breast cancer progression and drug resistance.

Breast cancer (BC) is one of the most common causes of cancer in the world and the second leading cause of cancer deaths among women. Mortality is associated mainly with the development of metastases. Identification of the mechanisms involved in metastasis formation is, therefore, a major public health issue.

  • Ref: Environ Health. 2020 Nov 17;19(1):117.
  • Année de publication : 2020
  • Auteurs : Koual M, Tomkiewicz C, Cano-Sancho G, Antignac JP, Bats AS, Coumoul X.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

In vivo comparison of the proangiogenic properties of chlordecone and three of its dechlorinated derivatives formed…

n situ chemical reduction (ISCR) has been identified as a possible way for the remediation of soils contaminated by chlordecone (CLD). Evidences provided by the literature indicate an association between the development of prostate cancer and CLD exposure (Multigner et al. 2010).

  • Ref: Environ Sci Pollut Res Int. 2020 Nov;27(33):40953-40962.
  • Année de publication : 2020
  • Auteurs : Alabed Alibrahim E, Legeay S, Billat PA, Bichon E, Guiffard I, Antignac JP, Legras P, Roux J, Bristeau S, Clere N, Faure S, Mouvet C.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Macrophages: Checking Toxicity of Fungal Metabolites in the Colon.

It is well known that the intestine absorbs nutrients, electrolytes, and water. Chikina et al. recently demonstrated that it is also able to sense, recognize, and block the absorption of toxins through a very sophisticated interactive cellular cooperation between novel subpopulations of macrophages and epithelial cells.

  • Ref: Trends Endocrinol Metab. 2020 Dec 17:S1043-2760(20)30248-4.
  • Année de publication : 2020
  • Auteurs : Blatzer M, Papon N, Delneste Y, Latgé JP.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast…

Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few years.

  • Ref: J Clin Oncol. 2020 Dec 1;38(34):3987-3998.
  • Année de publication : 2020
  • Auteurs : Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1…

Background: Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated.

  • Ref: J Immunother Cancer. 2020 Nov;8(2):e001631.
  • Année de publication : 2020
  • Auteurs : Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.

Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAFV600 wild-type advanced melanoma.

  • Ref: Ann Oncol. 2020 Dec 10:S0923-7534(20)43203-X.
  • Année de publication : 2020
  • Auteurs : Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with…

Purpose: Report results of the phase Ib dose-escalation/expansion study of triplet therapy with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor (ribociclib), mTOR inhibitor (everolimus), and endocrine therapy (exemestane).

  • Ref: Clin Cancer Res. 2020 Dec 15;26(24):6417-6428.
  • Année de publication : 2020
  • Auteurs : Bardia A, Modi S, Oliveira M, Cortes J, Campone M, Ma B, Dirix L, Weise A, Hewes B, Diaz-Padilla I, Han Y, Deshpande P, Samant TS, Lorenc KR, He W, Su F, Chavez-MacGregor M.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

French ccAFU guidelines – update 2020-2022: prostate cancer.

The purpose of the guidelines national committee ccAFU was to propose updated french guidelines for prostate cancer.

  • Ref: Prog Urol. 2020 Nov;30(12S):S136-S251.
  • Année de publication : 2020
  • Auteurs : Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont-Hankard G, Mathieu R, Ploussard G, Renard-Penna R, Brenot-Rossi I, Bruyere F, Cochet A, Crehange G, Cussenot O, Lebret T, Rebillard X, Soulié M, Brureau L, Méjean A.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Amélioration de la classification du risque intermédiaire du cancer de la prostate avec les données IRM…

Le cancer de la prostate de risque intermédiaire est désormais classé en pronostic favorable et défavorable, en fonction du score ISUP, du PSA, du toucher rectal et du pourcentage de biopsies positives. Notre objectif était d’évaluer l’apport de l’imagerie et des biopsies ciblées pour améliorer cette classification à partir de l’analyse du stade histopathologique après prostatectomie totale.

  • Ref: Prog Urol. 2020 Nov;30(13):776.
  • Année de publication : 2020
  • Auteurs : Thenault R, Gasmi A, Kaulanjan K, Goujon A, Courboin E, Manunta A, Verhoest G, Vincendeau S, Bensalah K, Khene Z, Peyronnet B, Mathieu R.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

A cohort study of banana plantation workers in the French West Indies: first mortality analysis (2000-2015).

Chlordecone, an organochlorine insecticide, was widely used in the French West Indies banana plantations. We set up a cohort of banana plantation workers who worked between 1973 and 1993, the period of authorized use of chlordecone. Vital status and causes of death were collected from French national registries.

  • Ref: Environ Sci Pollut Res Int. 2020 Nov;27(33):41014-41022.
  • Année de publication : 2020
  • Auteurs : Luce D, Dugas J, Vaidie A, Michineau L, El-Yamani M, Multigner L.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication